scispace - formally typeset
M

Martina Mittlböck

Researcher at Medical University of Vienna

Publications -  157
Citations -  5066

Martina Mittlböck is an academic researcher from Medical University of Vienna. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 36, co-authored 153 publications receiving 4524 citations. Previous affiliations of Martina Mittlböck include University of Vienna.

Papers
More filters
Journal ArticleDOI

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

TL;DR: A randomised, open-label, phase III, 4-arm trial comparing tamoxifen and goserelin versus anastrozole and zoledronic acid for preventing bone loss associated with adjuvant endocrine therapy and reports on long-term findings of bone-mineral density (BMD) during 3 years of treatment and 2 years after completing adjuant treatment with or without zoledronics acid.
Journal ArticleDOI

Explained variation for logistic regression

TL;DR: In this article, the authors review twelve measures that have been suggested or might be useful to measure explained variation in logistic regression models, and compare their performance in an empirical study.
Journal ArticleDOI

The prevalence of hemorrhoids in adults

TL;DR: Hemorrhoids occur frequently in the adult general population and a high BMI can be regarded as an independent risk factor for hemorrhoids.
Journal Article

TP53 Mutation and p53 Overexpression for Prediction of Response to Neoadjuvant Treatment in Breast Cancer Patients

TL;DR: TP53 mutations, as well as p53 protein overexpression, to be associated with response to chemotherapy, whereas clinical response to FEC was found to be dependent on normal p53, the cytotoxicity of paclitaxel was related to defective p53.
Journal ArticleDOI

Efficacy of liver transplantation for alcoholic cirrhosis with respect to recidivism and compliance.

TL;DR: Unwillingness to offer OLT to individuals with alcoholic liver disease because of failure to demonstrate 100% long-term abstinence appears difficult to defend in the face of good results in survival, compliance, and social rehabilitation.